Search results

7 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Awaiting development Remove Awaiting development filter
In consultation Remove In consultation filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Clinical guidelines Remove Clinical guidelines filter
Public health guidelines Remove Public health guidelines filter
Diagnostics guidance Remove Diagnostics guidance filter

OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Awaiting development [GID-HST10022] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Awaiting development
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Awaiting development [GID-HST10019] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Awaiting development
Leriglitazone for treating andrenoleukodystrophy [ID3903]

Awaiting development [GID-HST10049] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Awaiting development
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

Awaiting development [GID-HST10039] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Awaiting development
VTS-270 for treating Niemann-Pick type C1 (ID1267)

Awaiting development [GID-HST10020] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Awaiting development
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

Awaiting development [GID-HST10032] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Awaiting development
Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) [ID3927]

Awaiting development [GID-HST10046] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Awaiting development

Filter (8 in use)

Type 1 selected

Status 2 selected

Last updated

Guidance programme 5 selected

7 results

OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Leriglitazone for treating andrenoleukodystrophy [ID3903]

Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

VTS-270 for treating Niemann-Pick type C1 (ID1267)

Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) [ID3927]